{"title":"Mechanisms of Itch in Atopic Dermatitis.","authors":"Yayoi Kamata, Mitsutoshi Tominaga, Kenji Takamori","doi":"10.14789/ejmj.JMJ24-0036-R","DOIUrl":null,"url":null,"abstract":"<p><p>Atopic dermatitis (AD) is a common inflammatory skin disease characterized by recurrent eczematous lesions and intense itch. The pathological mechanism of AD involves a complex interaction between skin barrier dysfunction and a predominantly T helper (Th) 2-skewed immune dysregulation. The dysfunctional skin barrier in AD enhances antigen penetration, exacerbating allergic reactions. Scratching further damages the skin barrier, worsens dryness and increases the release of pro-inflammatory mediators, perpetuating the itch-scratch cycle. Breaking this cycle with appropriate treatments is vital. Th2 cells secrete interleukin (IL)-4, IL-13 and IL-31 which play keys roles in AD pathogenesis. IL-31 directly induces pruritus, while IL-4 and IL-13 enhance itching. An increased density of intraepidermal nerve fibers has been observed in AD lesions in a disease-state-dependent manner. In normal skin, both semaphorin 3A (Sema3A; a nerve repulsion factor) and nerve growth factor (NGF; a nerve elongation factor) are expressed. However, in AD lesions, Sema3A expression decreases while NGF expression increases. These findings suggest that epidermal nerve density is regulated by a fine balance between Sema3A and NGF, with Sema3A playing a key role in itch sensitivity in AD. In healthy skin, Sema3A is produced during the early-stage of differentiation of keratinocytes and moves into the upper epidermis. The levels of Sema3A and the density of epidermal nerve fibers may vary depending on the disease state of AD. Our future research will focus on the regulatory mechanisms of Sema3A in skin, and potential clinical applications.</p>","PeriodicalId":520470,"journal":{"name":"Juntendo medical journal","volume":"71 1","pages":"43-50"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11915750/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Juntendo medical journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14789/ejmj.JMJ24-0036-R","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Atopic dermatitis (AD) is a common inflammatory skin disease characterized by recurrent eczematous lesions and intense itch. The pathological mechanism of AD involves a complex interaction between skin barrier dysfunction and a predominantly T helper (Th) 2-skewed immune dysregulation. The dysfunctional skin barrier in AD enhances antigen penetration, exacerbating allergic reactions. Scratching further damages the skin barrier, worsens dryness and increases the release of pro-inflammatory mediators, perpetuating the itch-scratch cycle. Breaking this cycle with appropriate treatments is vital. Th2 cells secrete interleukin (IL)-4, IL-13 and IL-31 which play keys roles in AD pathogenesis. IL-31 directly induces pruritus, while IL-4 and IL-13 enhance itching. An increased density of intraepidermal nerve fibers has been observed in AD lesions in a disease-state-dependent manner. In normal skin, both semaphorin 3A (Sema3A; a nerve repulsion factor) and nerve growth factor (NGF; a nerve elongation factor) are expressed. However, in AD lesions, Sema3A expression decreases while NGF expression increases. These findings suggest that epidermal nerve density is regulated by a fine balance between Sema3A and NGF, with Sema3A playing a key role in itch sensitivity in AD. In healthy skin, Sema3A is produced during the early-stage of differentiation of keratinocytes and moves into the upper epidermis. The levels of Sema3A and the density of epidermal nerve fibers may vary depending on the disease state of AD. Our future research will focus on the regulatory mechanisms of Sema3A in skin, and potential clinical applications.